Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ERAS-0015 · 1 trial · 1 indication
Based on toxicities observed
Based on toxicities observed
Based on toxicities observed
Incidence and severity of treatment-emergent AEs and serious AEs
Maximum plasma concentration of ERAS-0015
Time to achieve maximum plasma concentration of ERAS-0015
Area under the plasma concentration-time curve of ERAS-0015
Half-life of ERAS-0015
| Arm | Type | Description |
|---|---|---|
| ERAS-0015 Monotherapy Dose Optimization. | EXPERIMENTAL | Escalating doses of ERAS-0015 administered orally. |
| ERAS-0015 Combination Dose Optimization | EXPERIMENTAL | ERAS-0015 administered orally with another investigational agent. |
| Name | Type | Description |
|---|---|---|
| ERAS-0015 | DRUG | ERAS-0015 Administered orally |
| ERAS-0015 in combination | DRUG | ERAS-0015 Administered orally and in combination with either KEYTRUDA® (pembrolizumab) via IV administration or Vectibix (panitumumab) via IV administration. |
Inclusion Criteria: * Age ≥ 18 years * Willing and able to give written informed consent * Pathological documentation of tumor type and mutation prior to the first dose of study drug(s), for applicable cohorts. * There is no available standard systemic therapy available for the patient's tumor hist...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ERAS-0015 is an investigational small molecule being developed for the treatment of metastatic solid tumors. It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug is being studied in patients with advanced or metastatic solid tumors.
ERAS-0015 targets RAS, a gene that is frequently mutated in various cancers. By targeting RAS, the drug aims to interfere with signaling pathways that drive tumor growth. This mechanism is being evaluated in a Phase 1 clinical trial for patients with metastatic solid tumors.
ERAS-0015 is being developed by Erasca, Inc., a biopharmaceutical company. Erasca is publicly traded under the ticker symbol ERAS. The company is conducting a Phase 1 clinical trial to evaluate the safety and efficacy of ERAS-0015 in patients with metastatic solid tumors.
ERAS-0015 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 1 trial is recruiting patients with advanced or metastatic solid tumors to assess the drug's safety, tolerability, and preliminary efficacy.
ERAS-0015 is being studied in a Phase 1 clinical trial with the identifier NCT06983743. The trial, titled "A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors," is currently recruiting participants in the United States. The study aims to enroll 600 patients aged 18 years and older.
Yes, ERAS-0015 has received Fast Track designation from the FDA. This designation is intended to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need. The drug is currently in Phase 1 clinical development for metastatic solid tumors.